NASDAQ:SRRA - Sierra Oncology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.62 -0.17 (-6.09 %)
(As of 05/20/2018 07:44 AM ET)
Previous Close$2.62
Today's Range$2.58 - $2.95
52-Week Range$1.10 - $4.09
Volume654,724 shs
Average Volume471,550 shs
Market Capitalization$194.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.37

About Sierra Oncology (NASDAQ:SRRA)

Sierra Oncology logoSierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SRRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRRA
CUSIPN/A
Phone604-558-6536

Debt

Debt-to-Equity RatioN/A
Current Ratio24.15
Quick Ratio24.15

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.76 per share
Price / Book1.49

Profitability

EPS (Most Recent Fiscal Year)($0.84)
Net Income$-42,010,000.00
Net MarginsN/A
Return on Equity-38.45%
Return on Assets-36.40%

Miscellaneous

Employees57
Outstanding Shares74,310,000

Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

How were Sierra Oncology's earnings last quarter?

Sierra Oncology (NASDAQ:SRRA) posted its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.02. View Sierra Oncology's Earnings History.

What are Wall Street analysts saying about Sierra Oncology stock?

Here are some recent quotes from research analysts about Sierra Oncology stock:
  • 1. According to Zacks Investment Research, "Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada. " (5/16/2018)
  • 2. Jefferies Group LLC analysts commented, "under-the-radar" clinical program shows innovation and value.As such, Jefferies upgraded shares of the company from Hold to Buy and lifted its price target from $1.50 to $5.At the time of writing, shares of Sierra Oncology were jumping 9.76 percent to $1.80.Analyst Maury Raycroft noted that Sierra Oncology is rapidly advancing SRA737 through dose-escalation in two clinical studies. SRA737 is a potent, highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1, which is being investigated in two phase 1 clinical trials in patients with advanced cancer.The analyst believes the market opportunity will continue to evolve and grow along with increased genetic testing and understanding, with potential for ‘737 success in several tumor-agnostic indications.The analyst noted that the company is running two trials, one assessing ‘737 as a monotherapy and another with ‘737+ low-dose gem. In mono settings, the analyst noted that ‘737 can follow a similar path as PARPs and may be used in points with DNA repair mutations. See also: Attention Biotech Investors, Here's Your PDUFA Primer For October Meanwhile, in combo study, the analyst said the company is using a biology-driven design, where a low dose is used to induce replication stress, increasing cancer cell reliance on Chk1. Additionally, the analyst said pharma enthusiasm and data validate Chk1 inhibition as a clinically-relevant mechanism of action. Also, SRA737 safety update at ASCO'17 de-risks further, the analyst added.Among the upcoming catalysts are:‘737 data due in Feb 2018 and the second-half of 2018.Updates throughout the next 12-18 months for competitor Chk1s such as Eli Lilly and Co LLY)'s prexasertib and Array Biopharma Inc (NASDAQ: ARRY)'s GDC-0575.Pre-clinical Chk1 abstracts, supporting the company's strategy, such as SRA737+low-dose gem abstract and a prexasertib one on Chk1 PD-L1 regulation."Importantly, we believe SRRA's clinical strategy is differentiated and innovative — a smarter strategy — selecting for pts w/ specific genetic driver mutations that may make them most likely to respond to '737," Jefferies added."We would buy ahead of 1Q18 data." (10/23/2017)

Who are some of Sierra Oncology's key competitors?

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the folowing people:
  • Dr. Nicholas R. Glover, Chief Exec. Officer, Pres and Director (Age 49)
  • Dr. Angie J. You Ph.D., Head of Commercial and Chief Bus. & Strategy Officer (Age 45)
  • Dr. Barbara Klencke M.D., Chief Devel. Officer (Age 61)
  • Mr. Sukhi Jagpal CPA, CA, CBV, MBA, Chief Financial Officer (Age 44)
  • Dr. Keith E. Anderson Ph.D., Sr. VP of Technical Operations (Age 49)

Has Sierra Oncology been receiving favorable news coverage?

Media headlines about SRRA stock have trended positive on Sunday, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sierra Oncology earned a news sentiment score of 0.33 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 48.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by many different of institutional and retail investors. Top institutional investors include Prosight Management LP (3.42%), Millennium Management LLC (3.07%), Point72 Asset Management L.P. (2.69%), Abingworth LLP (1.94%), Iguana Healthcare Management LLC (1.35%) and Sphera Funds Management LTD. (1.35%). Company insiders that own Sierra Oncology stock include Angie You and James N Topper. View Institutional Ownership Trends for Sierra Oncology.

Which institutional investors are buying Sierra Oncology stock?

SRRA stock was bought by a variety of institutional investors in the last quarter, including Prosight Management LP, Point72 Asset Management L.P., Abingworth LLP, Millennium Management LLC, Dimensional Fund Advisors LP, Sphera Funds Management LTD., Neuberger Berman Group LLC and Spark Investment Management LLC. Company insiders that have bought Sierra Oncology stock in the last two years include Angie You and James N Topper. View Insider Buying and Selling for Sierra Oncology.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $2.62.

How big of a company is Sierra Oncology?

Sierra Oncology has a market capitalization of $194.69 million. The biotechnology company earns $-42,010,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Sierra Oncology employs 57 workers across the globe.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150 -885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected]


MarketBeat Community Rating for Sierra Oncology (SRRA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe SRRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sierra Oncology (NASDAQ:SRRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Sierra Oncology in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$4.00$4.00
Price Target Upside: N/AN/A143.90% upside143.90% upside

Sierra Oncology (NASDAQ:SRRA) Consensus Price Target History

Price Target History for Sierra Oncology (NASDAQ:SRRA)

Sierra Oncology (NASDAQ:SRRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Jefferies GroupUpgradeHold ➝ BuyN/AView Rating Details
3/10/2017SunTrust BanksUpgradeHold ➝ Buy$4.00HighView Rating Details
3/6/2017WedbushReiterated RatingOutperform$4.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Sierra Oncology (NASDAQ:SRRA) Earnings History and Estimates Chart

Earnings by Quarter for Sierra Oncology (NASDAQ:SRRA)

Sierra Oncology (NASDAQ:SRRA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.78)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.21)($0.21)($0.21)
Q2 20182($0.22)($0.16)($0.19)
Q3 20182($0.23)($0.16)($0.20)
Q4 20182($0.19)($0.17)($0.18)

Sierra Oncology (NASDAQ SRRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1($0.21)($0.19)ViewN/AView Earnings Details
2/27/2018Not Specified($0.22)($0.20)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.21)($0.19)ViewN/AView Earnings Details
8/10/20176/30/2017($0.21)($0.20)ViewN/AView Earnings Details
5/9/20173/31/2017($0.19)($0.26)ViewN/AView Earnings Details
3/2/201712/31/2016($0.29)($0.30)ViewN/AView Earnings Details
11/10/2016Q3($0.29)($0.50)ViewN/AView Earnings Details
8/12/2016Q216($0.38)($0.43)ViewN/AView Earnings Details
5/10/2016Q1($0.42)($0.35)ViewN/AView Earnings Details
3/3/2016Q415($0.58)($0.38)ViewN/AView Earnings Details
11/5/2015Q315($0.48)($11.03)ViewN/AView Earnings Details
8/21/2015Q215($104.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sierra Oncology (NASDAQ:SRRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sierra Oncology (NASDAQ SRRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.61%
Institutional Ownership Percentage: 42.29%
Insider Trading History for Sierra Oncology (NASDAQ:SRRA)
Insider Trading History for Sierra Oncology (NASDAQ:SRRA)

Sierra Oncology (NASDAQ SRRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2017Angie YouInsiderBuy30,000$1.43$42,900.00133,252View SEC Filing  
2/14/2017James N TopperDirectorBuy5,925,926$1.35$8,000,000.10View SEC Filing  
3/22/2016Wendy ChapmanSVPSell3,000$7.01$21,030.003,000View SEC Filing  
2/22/2016Wendy ChapmanSVPSell3,000$7.06$21,180.003,000View SEC Filing  
1/22/2016Wendi RodiguezainsiderSell3,000$9.86$29,580.00156,276View SEC Filing  
1/22/2016Wendy ChapmanSVPSell5,000$9.39$46,950.00View SEC Filing  
1/15/2016Nicholas GloverCEOSell5,000$10.04$50,200.00View SEC Filing  
1/12/2016Chandra D. LovejoySVPSell20,973$11.29$236,785.17View SEC Filing  
7/21/2015Orbimed Advisors LlcDirectorBuy175,000$17.00$2,975,000.00View SEC Filing  
7/21/2015Vivo Ventures Vii, LlcInsiderBuy220,000$17.00$3,740,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sierra Oncology (NASDAQ SRRA) News Headlines

Source:
DateHeadline
Sierra Oncology (SRRA) Upgraded to Hold by Zacks Investment ResearchSierra Oncology (SRRA) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:43 PM
 Analysts Expect Sierra Oncology (SRRA) Will Post Earnings of -$0.23 Per Share Analysts Expect Sierra Oncology (SRRA) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - May 14 at 11:12 AM
Sierra Oncology (SRRA) Announces  Earnings ResultsSierra Oncology (SRRA) Announces Earnings Results
www.americanbankingnews.com - May 11 at 8:59 PM
Sierra Oncology, Inc: 1Q Earnings SnapshotSierra Oncology, Inc: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:14 AM
Sierra Oncology Reports First Quarter ResultsSierra Oncology Reports First Quarter Results
finance.yahoo.com - May 10 at 9:14 AM
Sierra Oncology (SRRA) Upgraded by ValuEngine to "Buy"Sierra Oncology (SRRA) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - May 2 at 6:06 PM
Sierra Oncology (SRRA) to Release Quarterly Earnings on MondaySierra Oncology (SRRA) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 12:34 PM
 Analysts Anticipate Sierra Oncology (SRRA) to Announce -$0.22 EPS Analysts Anticipate Sierra Oncology (SRRA) to Announce -$0.22 EPS
www.americanbankingnews.com - April 26 at 11:11 PM
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual MeetingSierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting
finance.yahoo.com - April 17 at 9:24 AM
Zacks: Brokerages Anticipate Sierra Oncology Inc (SRRA) Will Announce Earnings of -$0.22 Per ShareZacks: Brokerages Anticipate Sierra Oncology Inc (SRRA) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 10 at 1:24 AM
Sierra Oncology (SRRA) Upgraded at Jefferies GroupSierra Oncology (SRRA) Upgraded at Jefferies Group
www.americanbankingnews.com - April 6 at 11:11 AM
Sierra Oncology (SRRA) Lifted to Hold at ValuEngineSierra Oncology (SRRA) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 12:00 AM
Sierra Oncology (SRRA) Presents At BioCenturys 25th Annual Future Leaders In The Biotech Industry Conference - SlideshowSierra Oncology (SRRA) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow
seekingalpha.com - March 27 at 4:42 PM
-$0.22 EPS Expected for Sierra Oncology Inc (SRRA) This Quarter-$0.22 EPS Expected for Sierra Oncology Inc (SRRA) This Quarter
www.americanbankingnews.com - March 24 at 1:16 AM
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York - PR Newswire (press release)Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York - PR Newswire (press release)
www.prnewswire.com - March 19 at 4:41 PM
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New YorkSierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York
finance.yahoo.com - March 19 at 9:12 AM
Due Diligence Ramp-Up: Sierra Oncologys DNA Damage Gamble - Seeking AlphaDue Diligence Ramp-Up: Sierra Oncology's DNA Damage Gamble - Seeking Alpha
seekingalpha.com - March 10 at 5:43 PM
PTC Therapeutics (PTCT) & Sierra Oncology (SRRA) Critical ReviewPTC Therapeutics (PTCT) & Sierra Oncology (SRRA) Critical Review
www.americanbankingnews.com - March 9 at 9:36 PM
-$0.21 EPS Expected for Sierra Oncology Inc (SRRA) This Quarter-$0.21 EPS Expected for Sierra Oncology Inc (SRRA) This Quarter
www.americanbankingnews.com - March 6 at 7:17 PM
SunTrust Banks Comments on Sierra Oncology Incs FY2022 Earnings (SRRA)SunTrust Banks Comments on Sierra Oncology Inc's FY2022 Earnings (SRRA)
www.americanbankingnews.com - March 5 at 9:26 AM
Sierra Oncology Inc to Post FY2019 Earnings of ($0.78) Per Share, Wedbush Forecasts (SRRA)Sierra Oncology Inc to Post FY2019 Earnings of ($0.78) Per Share, Wedbush Forecasts (SRRA)
www.americanbankingnews.com - March 5 at 8:14 AM
AWH Capital L.P. Acquires Shares of 685,000 Sierra Oncology Inc (SRRA)AWH Capital L.P. Acquires Shares of 685,000 Sierra Oncology Inc (SRRA)
www.americanbankingnews.com - March 5 at 4:52 AM
Sierra Oncology (SRRA) Downgraded by Zacks Investment Research to "Sell"Sierra Oncology (SRRA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 2 at 9:56 PM
Analysts Set Expectations for Sierra Oncology Incs FY2022 Earnings (SRRA)Analysts Set Expectations for Sierra Oncology Inc's FY2022 Earnings (SRRA)
www.americanbankingnews.com - March 2 at 5:30 PM
Jefferies Group Equities Analysts Decrease Earnings Estimates for Sierra Oncology Inc (SRRA)Jefferies Group Equities Analysts Decrease Earnings Estimates for Sierra Oncology Inc (SRRA)
www.americanbankingnews.com - March 2 at 1:00 PM
Sierra Oncology (SRRA) Plans Offering of Common StockSierra Oncology (SRRA) Plans Offering of Common Stock
www.streetinsider.com - March 2 at 8:59 AM
Sierra Oncology Announces Proposed Public Offering of Common StockSierra Oncology Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 1 at 5:11 PM
Jefferies Group Weighs in on Sierra Oncology Incs Q1 2018 Earnings (SRRA)Jefferies Group Weighs in on Sierra Oncology Inc's Q1 2018 Earnings (SRRA)
www.americanbankingnews.com - March 1 at 7:20 AM
Sierra Oncology (SRRA) Posts Quarterly  Earnings Results, Beats Expectations By $0.02 EPSSierra Oncology (SRRA) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - February 28 at 10:32 AM
Sierra Oncology (SRRA) and Janssen Sign Supply Agreement for Prostate Cancer StudySierra Oncology (SRRA) and Janssen Sign Supply Agreement for Prostate Cancer Study
www.streetinsider.com - February 28 at 9:00 AM
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer StudySierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study
finance.yahoo.com - February 27 at 9:05 AM
Sierra Oncology Significantly Expands Clinical Development ProgramSierra Oncology Significantly Expands Clinical Development Program
finance.yahoo.com - February 27 at 9:05 AM
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual MeetingSierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting
finance.yahoo.com - February 21 at 9:04 AM
 Brokerages Anticipate Sierra Oncology Inc (SRRA) Will Post Earnings of -$0.20 Per Share Brokerages Anticipate Sierra Oncology Inc (SRRA) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - February 18 at 3:14 AM
Sierra Oncology (SRRA) Presents At BIO CEO & Investor Conference - SlideshowSierra Oncology (SRRA) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 4:12 PM
Sierra Oncology to host Program Update in New York on February 27thSierra Oncology to host Program Update in New York on February 27th
finance.yahoo.com - February 6 at 9:23 AM
Brokerages Expect Sierra Oncology Inc (SRRA) to Post ($0.20) Earnings Per ShareBrokerages Expect Sierra Oncology Inc (SRRA) to Post ($0.20) Earnings Per Share
www.americanbankingnews.com - January 17 at 1:18 PM
Zacks: Brokerages Expect Sierra Oncology Inc (SRRA) Will Post Earnings of -$0.20 Per ShareZacks: Brokerages Expect Sierra Oncology Inc (SRRA) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - January 15 at 5:36 AM
4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE)4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE)
finance.yahoo.com - January 10 at 4:18 PM
Analyzing Sierra Oncology (SRRA) & Its RivalsAnalyzing Sierra Oncology (SRRA) & Its Rivals
www.americanbankingnews.com - January 8 at 11:06 PM
Head-To-Head Review: Sierra Oncology (SRRA) and Its RivalsHead-To-Head Review: Sierra Oncology (SRRA) and Its Rivals
www.americanbankingnews.com - January 5 at 7:18 AM
Sierra Oncology to Present at the Biotech Showcase in San FranciscoSierra Oncology to Present at the Biotech Showcase in San Francisco
finance.yahoo.com - January 3 at 9:13 AM
Sierra Oncology (SRRA) versus Its Peers Financial SurveySierra Oncology (SRRA) versus Its Peers Financial Survey
www.americanbankingnews.com - January 2 at 1:20 PM
Comparing Sierra Oncology (SRRA) and Its PeersComparing Sierra Oncology (SRRA) and Its Peers
www.americanbankingnews.com - December 30 at 7:42 AM
Zacks: Brokerages Anticipate Sierra Oncology Inc (SRRA) to Announce -$0.20 Earnings Per ShareZacks: Brokerages Anticipate Sierra Oncology Inc (SRRA) to Announce -$0.20 Earnings Per Share
www.americanbankingnews.com - December 29 at 9:28 AM
Sierra Oncology (SRRA) & Its Rivals Critical ComparisonSierra Oncology (SRRA) & Its Rivals Critical Comparison
www.americanbankingnews.com - December 29 at 3:28 AM
Analysts Anticipate Sierra Oncology Inc (SRRA) to Post ($0.20) EPSAnalysts Anticipate Sierra Oncology Inc (SRRA) to Post ($0.20) EPS
www.americanbankingnews.com - December 28 at 5:04 PM
Sierra Oncology (SRRA) in Focus: Stock Moves 10.5% Higher - NasdaqSierra Oncology (SRRA) in Focus: Stock Moves 10.5% Higher - Nasdaq
www.nasdaq.com - December 28 at 8:01 AM
Sierra Oncology (SRRA) in Focus: Stock Moves 10.5% HigherSierra Oncology (SRRA) in Focus: Stock Moves 10.5% Higher
finance.yahoo.com - December 27 at 2:27 PM
 Sierra Oncology Inc (SRRA) Receives Average Recommendation of "Strong Buy" from Brokerages Sierra Oncology Inc (SRRA) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 16 at 3:24 PM

SEC Filings

Sierra Oncology (NASDAQ:SRRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sierra Oncology (NASDAQ:SRRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sierra Oncology (NASDAQ SRRA) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.